Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17103344 | 0.82 | — | — | |
| SCHEMBL2249685 | 0.76 | KIF11 (0.31) | — | |
| SCHEMBL600997 | 0.67 | NPC1 (0.30) | — | |
| SCHEMBL29023462 | 0.64 | ACHE (0.34) | — | |
| SCHEMBL292437 | 0.62 | KIF11 (0.38) | KDM5AKDM4C | |
| SCHEMBL2428208 | 0.62 | — | — | |
| SCHEMBL1883155 | 0.62 | — | — | |
| SCHEMBL352259 | 0.62 | — | — | |
| SCHEMBL1448773 | 0.62 | — | — | |
| SCHEMBL4465626 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | claimed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-111909082-B | Pyridine hydrazone derivatives, and preparation method and application thereof | 湖南大学 | 2022-09-13 | — | — | CN | claimed |
| CN-114341124-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2022-04-12 | — | — | CN | claimed |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-12-09 | — | — | US | claimed |
| CN-111909082-A | Pyridine hydrazone derivatives, and preparation method and application thereof | 湖南大学 | 2020-11-10 | — | — | CN | claimed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | claimed |
| WO-2018045182-A1 | DISUBSTITUTED AND TRISUBTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS | THE BOARD OF REGENTS OF HTE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-03-08 | — | — | WO | claimed |
| EP-2389066-B1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LTD (GB) | 2017-07-05 | — | — | EP | claimed |
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | claimed |
| EP-2375898-B1 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-09-16 | — | — | EP | claimed |
| WO-2015028989-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-05 | — | — | WO | claimed |
| US-8895474-B2 | Herbicidally active cyclopentanediones and derivatives thereof, and their use in controlling weeds | SYNGENTA LIMITED (GB) | 2014-11-25 | — | — | US | claimed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | claimed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | claimed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | claimed |
| WO-2012135570-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | claimed |
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | claimed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PTP4A1, PPP5C | KDM5A 1417/4885KDM4C 2281/4885 |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | KDM5A 3721/4885KDM4C 3595/4885 |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | KDM5A 2012/4885KDM4C 2882/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | KDM5A 3381/4885KDM4C 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.